$ARTV

Banerjee Subhashis sold $12K of ARTV

Banerjee Subhashis (Chief Medical Officer) sold 1,100 shares of Artiva Biotherapeutics, Inc. (ARTV) at $11.16 on 2026-09-03.

Original reporting
SEC EDGAR · Banerjee Subhashis
Published Sep 4, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
medium confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The transaction is a routine sale with limited market impact.

02

Market read

Minor insider sale; unlikely to affect price or sector sentiment.

03

What to watch

The insider still holds 140,947 shares, indicating confidence despite the sale.

Relevance 3/10Novelty 2/10Timing: post filing 2026-09-04

Background

Form 4 filing from SEC EDGAR reporting an insider transaction.

Company-level read

Ticker impact

$ARTVNeutralMedium confidence
Context

Chief Medical Officer Banerjee Subhashis sold 1,100 shares for $12,271 on 2026-09-03 via an open‑market transaction.

Expected impact

minimal downward pressure, likely negligible

Evidence & confidence

The sale size ($12k) is tiny relative to market cap and insider holdings; no indication of distress.

Market effects

None; biotech sector not affected by a micro insider sale.

None; only a US‑listed micro‑cap is involved.

None

Counterpoint

Even small insider sales can signal concerns; monitor subsequent filings for pattern.

Key entities

  • Artiva Biotherapeutics, Inc.

    US‑listed biotech (NASDAQ: ARTV).

  • Banerjee Subhashis

    Chief Medical Officer of Artiva Biotherapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARTVMed

Artiva Biotherapeutics, Inc. (ARTV): Results of Operations and Financial Condition

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®’s potential to drive deep B-cell depletion and meaningful clinical activity, with a